Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the Memorial Sloan-Kettering Cancer Center experience (1972-1981).
From January 1, 1972 to December 31, 1981, sixty-five patients underwent pelvic exenteration as treatment for recurrent or persistent gynecologic malignancy at Memorial Sloan-Kettering Cancer Center. Cervical carcinoma was the disease most commonly treated by exenteration. The operative mortality of 9.2% represents an improvement over previous reports from this institution. After routine use of prophylactic minidose heparin, no cases of thrombophlebitis or pulmonary embolus occurred postoperatively. A 5-year survival rate of 23% warrants continued use of exenteration in carefully selected patients. The significant mortality and morbidity associated with pelvic exenteration preclude its use as a palliative procedure.
Lawhead
R A
RA
Department of Gynecology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Clark
D G
DG
Smith
D H
DH
Pierce
V K
VK
Lewis
J L
JL
D005260:Female; D005833:Genital Neoplasms, Female / Q000401:mortality / Q000601:surgery*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007412:Intestinal Fistula / Q000209:etiology; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000601:surgery; D010385:Pelvic Exenteration / Q000009:adverse effects / Q000401:mortality; D012074:Remission Induction; D012189:Retrospective Studies